Counterfeits, trade secret theft plague drug, device industry
In an economy driven by global competition, counterfeits and theft of trade secrets remain major hazards for U.S. drug and device companies, handing them an uneven playing field in some parts of the world.
When it comes to counterfeits, most of the problems can be traced to China, which the U.S. Trade Representative's (USTR) 2016 Special 301 Report refers to as "the manufacturing hub of counterfeit products." Together with Hong Kong, India and Singapore, China accounted for 97 percent of all counterfeit drugs seized at the U.S. border last year.
Boston Scientific flies the W flag
It took 10 years but Boston Scientific (BSX) may have finally overcome its ill-advised 2006 Guidant acquisition. The company's shares hit a decade high Wednesday, at one point spiking nearly 12 percent to $22.05 after knocking its first quarter sales out of the park. (MDD Perspectives)
Growing evidence supports clinical potential of new cancer tests
With a market opportunity in the billions (as much as $20 billion by some estimates), diagnostic companies are rushing the liquid biopsy floodgates with new tests designed to make finding and monitoring cancer as easy as a blood draw or urine sample. This week, in a two-part series, Medical Device Daily will explore both the business opportunities and the clinical potential of this growing market.